Business
UNIVERSAL IBOGAINE ANNOUNCES WORLD-CLASS CLINICAL TRIAL PARTNERS IN ADVANCE OF CLINICAL TRIAL APPLICATION OR IBOGAINE IN OPIOID USE DISORDER
UNIVERSAL IBOGAINE ANNOUNCES WORLD-CLASS CLINICAL TRIAL PARTNERS IN ADVANCE OF CLINICAL T...
About this update from Universal Ibogaine Inc
[{"type":"text","content":"\n \n \n \n UNIVERSAL IBOGAINE ANNOUNCES WORLD-CLASS CLINICAL TRIAL PARTNERS IN ADVANCE OF CLINICAL TRIAL APPLICATION OR IBOGAINE IN OPIOID USE DISORDER\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n CALGARY, AB\n \n ,\n \n Jan. 14, 2022\n \n /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) (\"\n \n UI\n \n \" or the \"\n \n Company\n \n \") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, is pleased to introduce its contract research organization\n \n (\"CRO\")\n \n partners who will enable UI's planned clinical trial in\n \n Canada\n \n to be conducted, subject to the required approval by Health Canada. UI is currently working with its CRO partners to finalize UI's study design in advance of an anticipated pre-clinical trial application meeting to soon be held with Health Canada.\n \n \n \n \n \n \n \n \n \n UI has selected Intrinsik Corp. (\"\n \n Intrinsik\n \n \"), an internationally recognized regulatory affairs consulting firm, to provide regulatory strategy and support for the preparation and submission of UI's Canadian Clinical Trial Application (\"\n \n CTA\"\n \n ), as well as follow-up and monitoring if a No Objection Letter (\n \n \"NOL\"\n \n ) is received from Health Canada. Intrinsik is comprised of an experienced team who have driven hundreds of successful clinical trials and investigational new drug applications and have collectively contributed to more than 20 new drug marketing applications. The group has over 25 regulatory affairs professionals based in its Canadian headquarters located in the greater\n \n Toronto\n \n area, and unparalleled expertise and experience related to Central Nervous System Disorders (CNS: the therapeutic area to which addiction and mental health disorders belong).\n \n \n Support for the development of the substance of the CTA package, as well as ultimately the operation of the clinical trial itself, is being provided by the world-class team at CATO Research Canada Inc. (\"\n \n CATO SMS\n \n \"). The CATO SMS team of ex...